Trials that use: Odds ratio
New to this method? Read the tutorial →
5,976 results
- Safety Study of XP12B in Women With Menorrhagia: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of XP12B in Women With Menorrhagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00113568).
- Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose: Complete Statistical AnalysisIndependent statistical analysis of Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital: Complete Statistical AnalysisIndependent statistical analysis of Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy: Complete Statistical AnalysisIndependent statistical analysis of Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying…
- Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos: Complete Statistical AnalysisIndependent statistical analysis of Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01396434).
- Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.: Complete Statistical AnalysisIndependent statistical analysis of Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.: primary endpoint results, effect estimate with confidence interval,…
- Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors: Complete Statistical AnalysisIndependent statistical analysis of Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali:…
- Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate: Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00319228).
- Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411: Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04101357).
- Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029): primary endpoint results, effect estimate with…
- Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002): primary endpoint results, effect estimate with confidence…
- Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid: primary endpoint results, effect estimate with…
- Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02068690).
- Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency: primary endpoint results, effect estimate with confidence interval,…
- Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03653208).
- Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian…
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04138043).
- Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran: primary endpoint results, effect…
- Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease: Complete Statistical AnalysisIndependent statistical analysis of Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SAGB-PMIndependent statistical analysis of Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00543140).
- SAGEIndependent statistical analysis of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02539459).